A Study to Evaluate a New Jaundice Stick Test (Bilistick)

October 1, 2018 updated by: University of Oxford

Field Evaluation of a Point-Of-Care Test for Serum Bilirubin Levels in Infants Born in a Tropical Limited-resource Setting.

This is an observational prospective study. The main purpose is to evaluate the stability of the Bilistick system in a humid and hot climate compared to the quantitative test for serum bilirubin (SBR) measurement currently used, the BR-501 total bilirubin meter, kept in a controlled environment.

The secondary aim is to assess the operational feasibility of the Bilistick system in a tropical limited-resource setting, when used by locally trained nurses.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

Study procedure:

  1. SBR will be measured in parallel with two tests during three distinct seasons. (Cold, hot, rainy). The Blood is from an extra capillary sample taken from a single heel prick done for routine SBR) BR-501 total bilirubin meter, the quantitative test for SBR currently used, will be kept in a controlled environment while the new bilirubin test (Bilistick system) will be exposed to tropical conditions.
  2. Trained nurses will use the Bilistick system observed by a qualified laboratory technician; Usability of the Bilistick system by the trained nurses will be evaluated via a 5-point Likert scale questionnaire and focus groups discussions.

Study Type

Observational

Enrollment (Actual)

180

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Tak
      • Mae Sot, Tak, Thailand, 63110
        • Shoklo Malaria Research Unit (SMRU)

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 day to 4 weeks (CHILD)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Infant seen in WPA clinic during the neonatal period (birth to 28 days of life).

Description

Inclusion Criteria:

  • Written or thumb print for informed consent from the parent
  • Infant born ≥ 35 weeks of gestational age
  • Infant who needs a routine SBR measurement
  • Infant in stable clinical condition prior to SBR measurement confirmed by the trained nurses

Exclusion Criteria:

The participant will not be enrolled in the study if ANY of the following applies:

  • Infant who already had 1 SBR measurement done with the Bilistick system
  • Last haematocrit measurement > 65% or no previous haematocrit measurement

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Infants
Infants requiring serum bilirubin (SBR) measurement seen in Wang Pha clinic (WPA) clinic.
  • One full capillary tube (50µl blood) will be used to measure the Hct level and the routine SBR using the BR-501 bilirubin meter machine (non-study procedure).
  • An additional half- filled capillary tube (25µl blood) will be used for the SBR measurement with the Bilistick system

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Comparison of the agreement of serum bilirubin measurement between the two tests in three different seasons
Time Frame: 18 months
The main outcome of interest is the potential effect of environmental conditions on the quantitative outcome of the Bilistick System, using BR-501 bilirubin meter machine as a reference. The Bland-Altman analysis will be used to compare the two tests.
18 months
Within each season, evaluation of the impact of temporal variation on the agreement of serum bilirubin measurement between the two tests.
Time Frame: 18 months
A linear regression analysis will be done to look for statistically significant effect of exposure time on the difference between the average total bilirubin serum levels of the two tests.
18 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Evaluation of the usability of the Bilistick system using a 5-point likert scale questionnaire and a focus group discussions
Time Frame: 18 months
5-point likert scale questionnaire will be filled individually by the trained nurses at the end of each defined season. Quantitative variables related to the secondary outcomes will be measured with the mean, median and ratio according to the distribution of the variable and compared with appropriated statistical test.
18 months
Perception by the trained nurses of the Bilistick system usability with a focus group discussion (FGD).
Time Frame: 18 months
The FGD will be centered around the answers obtained from the questionnaires and the concerns raised by the trained nurses and laboratory technicians during each recruitment period. Qualitative variable from the focus group will be analysed with Nvivo.
18 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Professor Rose McGready, MD, Shoklo Malaria Research Unit (SMRU)

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

January 25, 2017

Primary Completion (ACTUAL)

December 11, 2017

Study Completion (ACTUAL)

December 11, 2017

Study Registration Dates

First Submitted

September 22, 2016

First Submitted That Met QC Criteria

October 4, 2016

First Posted (ESTIMATE)

October 6, 2016

Study Record Updates

Last Update Posted (ACTUAL)

October 2, 2018

Last Update Submitted That Met QC Criteria

October 1, 2018

Last Verified

July 1, 2018

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • SMRU1606

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Jaundice

Clinical Trials on Blood sampling

3
Subscribe